07:58 AM EDT, 08/20/2024 (MT Newswires) -- Eli Lilly ( LLY ) said Tuesday that results from a three-year phase 3 study showed that weekly tirzepatide injections reduced the risk of developing type 2 diabetes by 94% in obese or overweight adults with pre-diabetes condition compared to placebo.

The phase 3 trial also observed sustained weight loss in the participants over the three-year treatment period, with those on the 15 mg dose of the drug seeing a 22.9% average decrease in body weight compared to 2.1% for placebo, the company said.

The study evaluated the safety and efficacy of tirzepatide in 1,032 obese and overweight adults with pre-diabetes over 176 weeks, followed by a 17-week off-treatment period during which participants began to regain weight and saw an increase in progression to diabetes, according to Eli Lilly ( LLY ).

Tirzepatide is approved in the US as Mounjaro for adults with type 2 diabetes and as Zepbound for obese or overweight adults, Eli Lilly ( LLY ) said.

Price: 936.56, Change: +14.75, Percent Change: +1.60